Skip to main content
Top
Published in: Clinical Rheumatology 1/2008

01-01-2008 | Original Article

HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies

Authors: Harun Peru, Oguz Soylemezoglu, Sevim Gonen, Aysun Cetinyurek, Sevcan Azime Bakkaloğlu, Necla Buyan, Enver Hasanoglu

Published in: Clinical Rheumatology | Issue 1/2008

Login to get access

Abstract

Henoch Schonlein purpura (HSP) is the most common vasculitis of childhood. Susceptibility to HSP and associated clinical heterogeneity in HSP may be conferred by a number of genetic loci, including the major histocompatibility complex. We aimed to investigate the implications of the human leukocyte antigen (HLA) class 1 alleles in susceptibility to HSP and determine the possible associations with renal, gastrointestinal (GI), and joint manifestations of the disease. 110 children with HSP (66 boys, 44 girls) and 250 unrelated healthy controls were enrolled in the study. The mean age was 8.65 ± 3.59 years. HSP was diagnosed on the basis of clinical and laboratory data according to the American College of Rheumatology classification. The diagnosis was supported with skin and/or kidney in most of the patients. Clinical and laboratory findings revealed: skin involvement in 110 (100%), joint manifestations in 82 (74.5%), GI symptoms in 58 (52.7%), and hematuria and/or proteinuria in 36 (32.7%) patients. HLA class 1 alleles were identified by DNA amplification, hybridized with specific primer sequences. Comparison of frequencies between patients and controls were made by using the Fisher’s exact test. Odds ratio (OR) was used as the measure of association. HLA A2, A11, and B35 antigens showed an increased risk for predisposition to HSP (OR = 1.714, 95%CI = 1.088–2.700, p = 0.020; OR = 2.185, 95%CI = 1.289–3.703, p = 0.003; and OR = 2.292, 95%CI = 1.451–3.619, p = 0.000, respectively), while HLA A1, B49, and B50 antigens revealed decreased risk for predisposition to HSP (OR = 4.739, 95%CI = 1.828–12.345, p = 0.001; OR = 3.268, 95%CI = 0.955–11.236, p = 0.047; and OR = 7.462, 95%CI = 0.975–55.555, p = 0.024, respectively). Considering the renal involvement and severity of proteinuria, there was no association with HLA class 1 alleles. Our results suggest that the increased frequency of HLA A2, A11, and B35 alleles in unselected pediatric HSP patient population and miscarrying of HLA A1, B49, and B50 could be considered as a risk factor for susceptibility to HSP.
Literature
1.
go back to reference Jin DK, Kohsaka T, Koo JW et al (1996) Complement 4 locus II gene deletion and DQA1*0301 gene: genetic risk factors for IgA nephropathy and Henoch Schonlein nephritis. Nephron 73:390–395PubMedCrossRef Jin DK, Kohsaka T, Koo JW et al (1996) Complement 4 locus II gene deletion and DQA1*0301 gene: genetic risk factors for IgA nephropathy and Henoch Schonlein nephritis. Nephron 73:390–395PubMedCrossRef
2.
go back to reference Amoroso A, Berrino M, Canale L et al (1997) Immunogenetics of Henoch–Schonlein disease. Eur J Immunogenet 24:323–333PubMedCrossRef Amoroso A, Berrino M, Canale L et al (1997) Immunogenetics of Henoch–Schonlein disease. Eur J Immunogenet 24:323–333PubMedCrossRef
3.
go back to reference Amoli MM, Thomson W, Hajeer AH et al (2002) HLA B*35 association with nephritis in Henoch–Schonlein purpura. J Rheumatol 29:948–949PubMed Amoli MM, Thomson W, Hajeer AH et al (2002) HLA B*35 association with nephritis in Henoch–Schonlein purpura. J Rheumatol 29:948–949PubMed
4.
go back to reference Amoli MM, Thomson W, Hajeer AH et al (2001) HLA-DRB1*01 association with Henoch–Schonlein purpura in patients from Northwest Spain. J Rheumatol 28:1266–1270PubMed Amoli MM, Thomson W, Hajeer AH et al (2001) HLA-DRB1*01 association with Henoch–Schonlein purpura in patients from Northwest Spain. J Rheumatol 28:1266–1270PubMed
5.
go back to reference Mills JA, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Henoch–Schonlein purpura. Arthritis Rheum 33:1114–1121PubMedCrossRef Mills JA, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Henoch–Schonlein purpura. Arthritis Rheum 33:1114–1121PubMedCrossRef
6.
go back to reference Soylemezoglu O, Ozkaya O, Erbas D et al (2002) Nitric oxide in Henoch Schonlein purpura. Scand J Rheumatol 31:271–274PubMedCrossRef Soylemezoglu O, Ozkaya O, Erbas D et al (2002) Nitric oxide in Henoch Schonlein purpura. Scand J Rheumatol 31:271–274PubMedCrossRef
7.
go back to reference Dababneh A, González-Gay MA, Garcia-Porrua C et al (1998) Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 25:2140–2145PubMed Dababneh A, González-Gay MA, Garcia-Porrua C et al (1998) Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 25:2140–2145PubMed
8.
go back to reference Weyand CM, Hicock KC, Hunder GG et al (1992) The HLA DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA DR molecule. J Clin Invest 90:2355–2361PubMedCrossRef Weyand CM, Hicock KC, Hunder GG et al (1992) The HLA DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA DR molecule. J Clin Invest 90:2355–2361PubMedCrossRef
9.
go back to reference Weyand CM, Hunder NN, Hicock KC et al (1994) HLA DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 37:514–520PubMedCrossRef Weyand CM, Hunder NN, Hicock KC et al (1994) HLA DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 37:514–520PubMedCrossRef
10.
go back to reference Combe B, Sany J, Le Quellec A et al (1998) Distribution of HLA DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol 25:94–98PubMed Combe B, Sany J, Le Quellec A et al (1998) Distribution of HLA DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol 25:94–98PubMed
11.
go back to reference Rauzy O, Fort M, Nourhashemi F et al (1998) Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 57:380–382PubMed Rauzy O, Fort M, Nourhashemi F et al (1998) Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 57:380–382PubMed
12.
go back to reference Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH et al (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 5:283–292 Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH et al (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 5:283–292
13.
go back to reference Glass D, Soter NA, Gibson D et al (1976) Association between HLA and cutaneous necrotizing venulitis. Arthritis Rheum 19:945–949PubMedCrossRef Glass D, Soter NA, Gibson D et al (1976) Association between HLA and cutaneous necrotizing venulitis. Arthritis Rheum 19:945–949PubMedCrossRef
14.
go back to reference Ostergaard JR, Storm K, Lamm LU (1990) Lack of association between HLA and Schonlein–Henoch purpura. Tissue Antigens 35:234–235PubMed Ostergaard JR, Storm K, Lamm LU (1990) Lack of association between HLA and Schonlein–Henoch purpura. Tissue Antigens 35:234–235PubMed
15.
go back to reference Nathwani D, Laing RB, Smith CC et al (1992) Recurrent post-infective Henoch Schonlein syndrome: a genetic influence related to HLA B35?. J Infect 25:205–210PubMedCrossRef Nathwani D, Laing RB, Smith CC et al (1992) Recurrent post-infective Henoch Schonlein syndrome: a genetic influence related to HLA B35?. J Infect 25:205–210PubMedCrossRef
16.
go back to reference Nyulassy S, Buc M, Sasinka M et al (1977) The HLA system in glomerulonephritis. Clin Immunol Immunopathol 7:319–323PubMedCrossRef Nyulassy S, Buc M, Sasinka M et al (1977) The HLA system in glomerulonephritis. Clin Immunol Immunopathol 7:319–323PubMedCrossRef
17.
go back to reference Freycon MT, Parchoux B, Dechelette E et al (1984) HLA and rheumatoid purpura with or without nephropathy. Pediatrie 39:525–532PubMed Freycon MT, Parchoux B, Dechelette E et al (1984) HLA and rheumatoid purpura with or without nephropathy. Pediatrie 39:525–532PubMed
18.
go back to reference Arellano J, Ojeda S, Vargas R et al (1990) Histocompatibility antigens and acute vascular purpura. Bol Med Hosp Infant Mex 47:620–623PubMed Arellano J, Ojeda S, Vargas R et al (1990) Histocompatibility antigens and acute vascular purpura. Bol Med Hosp Infant Mex 47:620–623PubMed
Metadata
Title
HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies
Authors
Harun Peru
Oguz Soylemezoglu
Sevim Gonen
Aysun Cetinyurek
Sevcan Azime Bakkaloğlu
Necla Buyan
Enver Hasanoglu
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0640-z

Other articles of this Issue 1/2008

Clinical Rheumatology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine